The impact of epoetin beta (recombinant human erythropoietin) on brain infarction area (BIA) and neurological status in a rat model of acute ischemic stroke (IS) induced by distal left internal carotid artery occlusion was investigated.
Methods
Adult male Sprague-Dawley rats (n = 30) were categorized into group 2 (IS only) and group 3 (IS plus intraperitoneal erythropoietin 5000 IU/kg at 0, 12, and 24 hours after IS). Healthy Sprague-Dawley rats (n = 10) served as group 1.
Results
Analysis of brain tissues showed larger BIA in group 2 than in group 3 (P < 0.001). Corner test identified highest frequency of left turn in group 2 (P < 0.05). The mRNA expressions of Bax, caspase 3, interleukin 18, toll-like receptor 4, and plasminogen activator inhibitor 1 were highest, whereas Bcl-2 was lowest in group 2 (P < 0.05). Lower CXCR4 and stromal cell-derived factor 1 expressions were noted in group 2 than in group 3 (P < 0.01). Immunohistofluorescence staining showed lower expressions of CXCR4, stromal cell-derived factor 1, von Willebrand factor, and doublecortin with higher number of apoptotic nuclei in group 2 than in group 3 (P < 0.001). Immunohistochemical staining demonstrated lower cellular proliferation and number of small vessels with higher glial fibrillary acid protein expression in group 2 than in group 3 (P < 0.01).
Conclusions
Erythropoietin significantly limited BIA and improved sensorimotor dysfunction after acute IS.
American Heart Association.Stroke Statistics. Dallas, TX: American Heart Association; 2002.
2.
HankeyGJ. Stroke: how large a public health problem, and how can the neurologist help?Arch Neurol. 1999;56:748–754.
3.
World Health Organization. World Health Report 1999-Making a Difference. Geneva, Switzerland: World Health Organization; 1999.
4.
AdamsHPJr, BendixenBH, KappelleLJ. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in AcuteStroke Treatment. Stroke. 1993;24:35–41.
5.
ChenZ, SandercockP, PanH, . Indications for early aspirin use in acute ischemic stroke: a combined analysis of 40Â 000 randomized patients from the Chinese Acute Stroke Trial and the International Stroke Trial. Stroke. 2000;31:1240–1249.
6.
GrauAJ, WeimarC, BuggleF. Risk factors, outcome, and treatment in subtypes of ischemic stroke: the German stroke data bank. Stroke. 2001;32:2559–2566.
7.
MuirKW, WeirCJ, MurrayGD. Comparison of neurological scales and scoring systems for acute stroke prognosis. Stroke. 1996;27:1817–1820.
8.
YipHK, LiouCW, ChangHW. Link between platelet activity and outcomes after an ischemic stroke. Cerebrovasc Dis. 2005;20:120–128.
9.
WahlgrenN, AhmedN, DavalosA. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet. 2007;369:275–282.
10.
WardlawJM, del ZoppoGJ, YamaguchiT. Thrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev. 2009;(3):CD000213.
11.
AdamsHPJr, delZoppo G, AlbertsMJ. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Circulation. 2007;115:e478–e534.
12.
BravataDM. Intravenous thrombolysis in acute ischaemic stroke: optimising its use in routine clinical practice. CNS Drugs. 2005;19:295–302.
13.
SandercockP, BergeE, DennisM, . Cost-effectiveness of thrombolysis with recombinant tissue plasminogen activator for acute ischemic stroke assessed by a model based on UK NHS costs. Stroke. 2004;35:1490–1497.
14.
ThomallaG, SobeskyJ, KohrmannM, . Two tales: hemorrhagic transformation but not parenchymal hemorrhage after thrombolysis is related to severity and duration of ischemia: MRI study of acute stroke patients treated with intravenous tissue plasminogen activator within 6 hours. Stroke. 2007;38:313–318.
15.
CalvilloL, LatiniR, KajsturaJ, . Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci. 2003;100:4802–4806.
16.
HirataA, MinaminoT, AsanumaH, . Erythropoietin enhances neovascularization of ischemic myocardium and improves left ventricular dysfunction after myocardial infarction in dogs. J Am Coll Cardiol. 2006;48:176–184.
17.
MoonC, KrawczykM, AhnD, . Erythropoietin reduces myocardial infarction and left ventricular functional decline after coronary artery ligation in rats. Proc Natl Acad Sci. 2003;100:11612–11617.
18.
TramontanoAF, MuniyappaR, BlackAD, . Erythropoietin protects cardiac myocytes from hypoxia-induced apoptosis through an Akt-dependent pathway. Biochem Biophys Res Commun. 2003;308:990–994.
19.
BrinesML, GhezziP, KeenanS, . Erythroypoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci. 2000;97:10526–10531.
20.
LinJS, ChenYS, ChiangHS, . Hypoxic preconditioning protects rat hearts against ischaemia-reperfusion injury: role of erythropoietin on progenitor cell mobilization. J Physiol. 2008;586:5757–5769.
21.
LipsicE, van der MeerP, HenningRH, . Timing of erythropoietin treatment for cardioprotection in ischemia/reperfusion. J Cardiovasc Pharmacol. 2004;44:473–479.
22.
vander Meer P, VoorsAA, LipsicE, . Erythropoietin in cardiovascular diseases. Eur Heart J. 2004;25:285–291.
23.
VillaP, BiginiP, MenniniT, . Erythropoietin selectively attenuates cytokine production and inflammation in cerebral ischemia by targeting neuronal apoptosis. J Exp Med. 2003;198:971–975.
24.
DigicayliogluM, LiptonSA. Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappaB signalling cascades. Nature. 2001;412:641–647.
25.
KawakamiM, SekiguchiM, SatoK, . Erythropoietin receptor-mediated inhibition of exocytotic glutamate release confers neuroprotection during chemical ischemia. J Biol Chem. 2001;276:39469–39475.
26.
WangL, ZhangZ, WangY, . Treatment of stroke with erythropoietin enhances neurogenesis and angiogenesis and improves neurological function in rats. Stroke. 2004;35:1732–1737.
27.
HuaY, SchallertT, KeepRF, . Behavioral tests after intracerebral hemorrhage in rat. Stroke. 2002;33:2478–2484.
28.
OzawaT, TobaK, KatoK, . Erythroid cells play essential roles in angiogenesis by bone marrow cell implantation. J Mol Cell Cardiol. 2006;40:629–638.
29.
BowieMB, McKnightKD, KentDG, . Hematopoietic stem cells proliferate until after birth and show a reversible phase-specific engraftment defect. J Clin Invest. 2006;116:2808–2816.
30.
KuciaM, RecaR, MiekusK, . Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: pivotal role of the SDF-1-CXCR4 axis. Stem Cells. 2005;23:879–894.
31.
WeiYJ, TangY, LiJ, . Cloning and expression pattern of dog SDF-1 and the implications of altered expression of SDF-1 in ischemic myocardium. Cytokine. 2007;40:52–59.
32.
KahnJ, BykT, Jansson-SjostrandL. Overexpression of CXCR4 on human CD34+ progenitors increases their proliferation, migration, and NOD/SCID repopulation. Blood. 2004;103:2942–2949.
33.
YamaguchiJ, KusanoKF, MasuoO, . Stromal cell-derived factor-1 effects on ex vivo expanded endothelial progenitor cell recruitment for ischemic neovascularization. Circulation. 2003;107:1322–1328.
34.
ZhangD, FanGC, ZhouX, . Over-expression of CXCR4 on mesenchymal stem cells augments myoangiogenesis in the infarcted myocardium. J Mol Cell Cardiol. 2008;44:281–292.
35.
AbbottJD, HuangY, LiuD, . Stromal cell-derived factor-1alpha plays a critical role in stem cell recruitment to the heart after myocardial infarction but is not sufficient to induce homing in the absence of injury. Circulation. 2004;110:3300–3305.
36.
HuX, DaiS, WuWJ, . Stromal cell derived factor-1 alpha confers protection against myocardial ischemia/reperfusion injury: role of the cardiac stromal cell derived factor-1 alpha CXCR4 axis. Circulation. 2007;116:654–663.
37.
SunCK, ChangLT, SheuJJ, . Bone marrow-derived mononuclear cell therapy alleviates left ventricular remodeling and improves heart function in rat-dilated cardiomyopathy. Crit Care Med. 2009;37:1197–1205.
38.
YipH-K, ChangL-T, WuC-J, . Autologous bone marrow-derived mononuclear cell therapy prevents the damage of viable myocardium and improves rat heart function following acute anterior myocardial infarction. Circulation J. 2008;72:1336–1345.
